case report
A 25-year-old male was presented to our hospital with projectile vomiting in March 2010. Brain magnetic resonance imaging (MRI) revealed multiple lesions with oval shaped hyperintensities on T1-weighted image [ Figure 1a ], and immunohistochemistry of the brain biopsy revealed large atypical CD20 and CD79α positive lymphoid cells. He was diagnosed as PCNSL of the diffuse large B-cell type and was treated with seven courses of chemotherapy (methotrexate [MTX] , vincristine, ifosfamide, and dexamethasone) followed by one course of brain radiotherapy (3690cGy/22f/30d for whole brain and DT900cGy/5f/7d for local) in a period of 19 months. Remarkable remission of the lesions was observed [ Figure 1b] . In October 2012, he was admitted to a local hospital with cataract and vitreous hemorrhage in the left eye and underwent combined phacoemulsification, intraocular lens implantation and vitrectomy. After surgery, however, his left eye had recalcitrant anterior chamber inflammation, vitreous haze, and increased intraocular pressure (IOP), and was referred to our center in March 2013. On admission, his best-corrected visual acuity (BCVA) was 1.2 in the right eye (OD) and 0.1 in the left eye (OS); IOP was 21 mmHg (1 mmHg = 0.133 kPa) OD and 34.1 mmHg OS; the left eye had mild anterior chamber inflammation with 1+ keratic precipitates, flare, and cells [ Figure 2a ], as well as scattered white lesions in the anterior chamber angle; dilated examination revealed vitreous opacity and a 
dIscussIon
Primary intraocular lymphoma (PIOL) is rare with an incidence of about 4.8/million and approximately 300 new cases each year in the United States. While it typically affects seniors aged 60-85 years old, younger patients have been reported. The vast majority of PIOL is diffuse large B-cell lymphoma involving vitreous-retina complex; PIOL originates in the ciliary body (PCBL) is extremely rare, [1] [2] [3] [4] and CBL of PCNSL, as is the case of our current patient, to the best of our knowledge, has not been reported.
Reported cases with ciliary body lymphoma were usually presented as mild anterior inflammation, secondary glaucoma, and concomitant iris infiltration; [1] [2] [3] [4] none had systemic or CNS involvement except for one case in whom skin was involved later. [2] Our current patient, however, was a young male who complained blurred vision in the left eye 3 years after the diagnosis of PCNSL (diffuse large B-cell), and a complete ophthalmic examination revealed mild anterior inflammation, scattered granular white lesions in the angle of anterior chamber, as well as vitreous opacity with unremarkable fundus; UBM revealed epiretinal deposits and ciliary body masses with almost 360° involved. PCBLs were generally extranodal marginal zone type lymphoma [3, 4] with few cases of T-cell or diffuse large B-cell types reported. [2, 3] In our patient, however, the diagnosis of diffuse large B-cell lymphoma was established by cytology combining flow cytometry of both brain and vitreous samples.
Currently, high-dose MTX combining other chemotherapeutic agents, followed by whole brain radiotherapy, is recommended for treatment of PCNSL; in cases with ocular involvement, intravitreal injection of MTX or rituximab and ocular radiotherapy are suggested. [5] These treatments have improved the survival of PCNSL to 3+ years. This patient had dramatic clinical responses to systemic chemotherapy combining brain radiotherapy on diagnosis of PCNSL in 2010, and to IMRT on diagnosis of ocular recurrence in 2013, providing more evidence to the effectiveness of the above-mentioned treatment modalities.
In conclusion, ciliary body recurrence of lymphoma should be taken into consideration in PCNSL patients who presented with anterior chamber inflammation, raised IOP and unremarkable fundus. UBM is useful for evaluation of ciliary body lymphoma, and a vitreous or tissue biopsy should be considered in these patients for histopathology, which is the gold standard for the diagnosis of PCNSL/PIOL. Combined treatments of chemotherapy with radiotherapy might extend the survival time and preserve visual acuity for patients with ciliary body lymphoma.
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